» Articles » PMID: 20688042

Long Lived Protection Against Pneumonic Tularemia is Correlated with Cellular Immunity in Peripheral, Not Pulmonary, Organs

Overview
Journal Vaccine
Date 2010 Aug 7
PMID 20688042
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Protection against the intracellular bacterium Francisella tularensis within weeks of vaccination is thought to involve both cellular and humoral immune responses. However, the relative roles for cellular and humoral immunity in long lived protection against virulent F. tularensis are not well established. Here, we dissected the correlates of immunity to pulmonary infection with virulent F. tularensis strain SchuS4 in mice challenged 30 and 90 days after subcutaneous vaccination with LVS. Regardless of the time of challenge, LVS vaccination protected approximately 90% of SchuS4 infected animals. Surprisingly, control of bacterial replication in the lung during the first 7 days of infection was not required for survival of SchuS4 infection in vaccinated mice. Control and survival of virulent F. tularensis strain SchuS4 infection within 30 days of vaccination was associated with high titers of SchuS4 agglutinating antibodies, and IFN-γ production by multiple cell types in both the lung and spleen. In contrast, survival of SchuS4 infection 90 days after vaccination was correlated only with IFN-γ producing splenocytes and activated T cells in the spleen. Together these data demonstrate that functional agglutinating antibodies and strong mucosal immunity are correlated with early control of pulmonary infections with virulent F. tularensis. However, early mucosal immunity may not be required to survive F. tularensis infection. Instead, survival of SchuS4 infection at extended time points after immunization was only associated with production of IFN-γ and activation of T cells in peripheral organs.

Citing Articles

Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent .

Roberts L, Wehrly T, Leighton I, Hanley P, Lovaglio J, Smith B J Immunol. 2022; 208(5):1180-1188.

PMID: 35149529 PMC: 8881340. DOI: 10.4049/jimmunol.2100915.


Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice.

Jessop F, Schwarz B, Scott D, Roberts L, Bohrnsen E, Hoidal J JCI Insight. 2022; 7(2).

PMID: 35076028 PMC: 8855831. DOI: 10.1172/jci.insight.155896.


Cutting Edge: Lung-Resident T Cells Elicited by SARS-CoV-2 Do Not Mediate Protection against Secondary Infection.

Roberts L, Jessop F, Wehrly T, Bosio C J Immunol. 2021; 207(10):2399-2404.

PMID: 34607940 PMC: 8578432. DOI: 10.4049/jimmunol.2100608.


Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity.

Roberts L, Schwarz B, Speranza E, Leighton I, Wehrly T, Best S iScience. 2021; 24(9):103025.

PMID: 34522865 PMC: 8426275. DOI: 10.1016/j.isci.2021.103025.


Differential Immune Response Following Intranasal and Intradermal Infection with Implications for Vaccine Development.

Nicol M, Williamson D, Place D, Kirimanjeswara G Microorganisms. 2021; 9(5).

PMID: 33946283 PMC: 8145380. DOI: 10.3390/microorganisms9050973.


References
1.
Huber B, Devinsky O, GERSHON R, CANTOR H . Cell-mediated immunity: delayed-type hypersensitivity and cytotoxic responses are mediated by different T-cell subclasses. J Exp Med. 1976; 143(6):1534-9. PMC: 2190218. DOI: 10.1084/jem.143.6.1534. View

2.
Forestal C, Malik M, Catlett S, Savitt A, Benach J, Sellati T . Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis. 2007; 196(1):134-7. DOI: 10.1086/518611. View

3.
Wherry W, Lamb B . Infection of man with Bacterium tularense. 1914. J Infect Dis. 2004; 189(7):1321-9. DOI: 10.1093/infdis/189.7.1321. View

4.
Elkins K, Colombini S, Meierovics A, Chu M, Chou A, Cowley S . Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma. Microbes Infect. 2009; 12(1):28-36. DOI: 10.1016/j.micinf.2009.09.012. View

5.
Dennis D, INGLESBY T, Henderson D, Bartlett J, Ascher M, Eitzen E . Tularemia as a biological weapon: medical and public health management. JAMA. 2001; 285(21):2763-73. DOI: 10.1001/jama.285.21.2763. View